Research Article
Improvement in Neuropathy Specific Quality of Life in Patients with Diabetes after Vitamin D Supplementation
Table 3
NeuroQoL measures from baseline to final visit.
| | NeuroQoL measures | Baseline | V2 | V3 | V4 | V5 |
| | Pain | 11.7 ± 4.1 | 11.3 ± 4.7 | 11.5 ± 4.4 | 11.3 ± 4.3 | 11.4 ± 3.9 | | (−/35) | 11 (9–14) | 10 (8–13) | 10 (8–14) | 10 (8–14) | 11 (9–13) | | Loss reduction | 4.9 ± 2.4 | 4.8 ± 2.4 | 4.8 ± 2.6 | 4.7 ± 2.6 | 4.6 ± 2.2 | | (−/15) | 4 (3–6) | 4 (3–6) | 4 (3–6) | 4 (3–6) | 4 (3–5) | | Diffuse sensory-motor symptoms | 6.1 ± 3.6 | 6.1 ± 3.6 | 6.1 ± 3.5 | 6.1 ± 3.4 | 6.5 ± 3.0 | | (−/15) | 5 (3–7) | 5 (3–8) | 5 (3–7) | 5 (3–7) | 6 (4–8) | | Limitations | 4.5 ± 2.5 | 4.6 ± 2.5 | 4.2 ± 1.9 | 4.2 ± 2.0 | 4.1 ± 2.0 | | (−/15) | 3 (3–5) | 3 (3–6) | 3 (3–5) | 3 (3–5) | 3 (3–5) | | Interpersonal | 6.3 ± 3.9 | 6.3 ± 4.1 | 5.6 ± 3.1 | 5.9 ± 3.5 | 5.6 ± 3.1 | | (−/20) | 4 (4–7) | 4 (4–7) | 4 (4–7) | 4 (4–7) | 4 (4–7) | | Emotional distress | 13.4 ± 8.1 | 12.1 ± 7.5 | 11.0 ± 6.4 | 11.0 ± 6.0 | 10.8 ± 5.4 | | (−/35) | 9 (7–20) | 7 (7–17) | 7 (7–13)∗ | 7 (7–14)∗ | 7 (7–15)∗∗ | | R QoL | 12.0 ± 6.3 | 11.4 ± 6.2 | 11.2 ± 5.4 | 11.5 ± 5.2 | 11.2 ± 4.7 | | (−/30) | 10 (7–16) | 9 (7–15) | 9 (7–14) | 10 (7–14) | 10 (8–13) | | Total QoL | 64.7 ± 24.3 | 62.3 ± 24.9 | 60.1 ± 21.8 | 60.2 ± 21.7 | 59.8 ± 18.2 | | (−/135) | 57 (45–78) | 54 (44–71) | 53 (44–70) | 54 (43–71) | 55 (45–70) |
|
|
Data are presented as mean ± SD and median (IQR). and .
|
